Screening for hepatitis C virus infection in Peking University People's Hospital in 2015-2018

Kong XiangSha; Yang RuiFeng; Zhang HaiYing; Ji Ying; Zhu Ling; Liu Yan; Wei Lai

doi:10.3969/j.issn.1001-5256.2019.08.012

Volume 35 Issue 8

Aug. 2019

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2019 > 35(8): 1710-1713

PDF( 2115 KB)

Screening for hepatitis C virus infection in Peking University People's Hospital in 2015-2018

DOI: 10.3969/j.issn.1001-5256.2019.08.012

Beijing Key Laboratory for Hepatitis C and Immunotherapy for Liver Diseases, Peking University Hepatology Institute, People's Hospital, Peking University

Research funding:

Received Date: 2019-03-27
Published Date: 2019-08-20

Abstract

Abstract

Objective To investigate missed detection in the screening for hepatitis C virus (HCV) infection in a general hospital in 2015-2018. Methods A retrospective analysis was performed for the data of 3659 patients who attended People's Hospital, Peking University, from 2015 to 2018 and underwent the detection of anti-HCV and HCV RNA. Architect I2000 by Abbott and Vitros 3600 by Johnson and Johnson were used to measure anti-HCV, and the Roche Cobas AmpliPrep/Cobas Taqman 96 automatic virus quantification system was used to measure HCV RNA. The specimens were collected from the patients with positive HCV RNA and negative anti-HCV, and Sanger sequencing was used to determine HCV genotype. The patients were followed up to observe the status of HCV infection and clinical conditions. The signal-to-cut-off (S/CO) ratio was used to express the results of anti-HCV detection. GraphPad Prism 5. 0 was used to plot the distribution map of the S/CO ratio of anti-HCV. Results Of all 3659 patients, 6 (0. 16%) had negative anti-HCV based on at least one reagent and positive HCV RNA, with a mean level of (6. 40 ± 1. 86) log10 IU/ml. Among these 6 patients, 5 (83%) had acute leukemia and 1 had respiratory disease; among these patients, 1 had good prognosis, 3 had poor prognosis, and 2 died. Conclusion When antibody is used as the primary screening method for HCV infection, the rate of missed detection reaches 0. 16%, and most of these patients have poor prognosis. HCV RNA detection should be performed for patients with immunodeficiency to avoid missed detection.
- hepacivirus,
- hepatitis C antibodies,
- viral load

FullText(HTML)

References(12)

References

[1] Chinese Society of Hepatology and Chinese Society of Infectious Disease, Chinese Medical Association. The guideline of prevention and treatment for hepatitis C:A 2015 update[J]. J Clin Hepatol, 2015, 31 (12) :1961-1979. (in Chinese) 中华医学会肝病学分会, 中华医学会感染病学分会.丙型肝炎防治指南 (2015年更新版) [J].临床肝胆病杂志, 2015, 31 (12) :1961-1979.

[2] WEI L, LIM SG, XIE Q, et al. Sofosbuvir-velpatasvir for treatment of chronic hepatitis C virus infection in Asia:A singlearm, open-label, phase 3 trial[J]. Lancet Gastroen Hepatol, 2019, 4 (2) :127-134.

[3] YANG RF, WEI L. Detection of hepatitis C virus infection[J].J Clin Hepatol, 2011, 27 (1) :1-7. (in Chinese) 杨瑞锋, 魏来.丙型肝炎病毒感染的检测[J].临床肝胆病杂志, 2011, 27 (1) :1-7.

[4] Centers for Disease Control and Prevention. Testing for HCV infection:An update of guidance for clinicians and laboratorians[J]. MMWR, 2013, 62 (18) :362-365.

[5] YANG R, GUAN W, WANG Q, et al. Performance evaluation and comparison of the newly developed Elecsys anti-HCV II assay with other widely used assays[J]. Clin Chim Acta, 2013, 426:95-101.

[6] RAO H, WEI L, LOPEZ-TALAVERA JC, et al. Distribution and clinical correlates of viral and host genotypes in Chinese patients with chronic hepatitis C virus infection[J]. J Gastroenterol Hepatol, 2014, 29 (3) :545-553.

[7] CHEN YS, LI L, CUI FQ, et al. A sero-epidemiological study on hepatitis in China[J]. Chin J Epidemiol, 2011, 32 (9) :888-891. (in Chinese) 陈园生, 李黎, 崔富强, 等.中国丙型肝炎血清流行病学研究[J].中华流行病学杂志, 2011, 32 (9) :888-891.

[8] European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2018[J]. J Hepatol, 2018, 69 (2) :461-511.

[9] SHEN LP, BI SL. Recent advances in molecular epidemiological methods for analyzing hepatitis C virus transmission[J].Chin J Microbiol Immunol, 2016, 36 (10) :779-782. (in Chinese) 沈立萍, 毕胜利.丙型肝炎病毒传播分子流行病学诊断技术研究进展[J].中华微生物和免疫学杂志, 2016, 36 (10) :779-782.

[10] POZZETTO B, MEMMI M, GARRAUD O, et al. Health careassociated hepatitis C virus infection[J]. World J Gastroenterol, 2014, 20 (46) :17265-17278.

[11] KYVERNITAKIS A, MAHALE P, POPAT UR, et al. Hepatitis C virus infection in patients undergoing hematopoietic cell transplantation in the era of direct-acting antiviral agents[J]. Biol Blood Marrow Transplant, 2016, 22 (4) :717-722.

[12] MEDICI MC, CHEZZI C, de CONTO F, et al. Evolving strategy for HCV testing in an Italian tertiary care hospital[J]. J Clin Virol, 2016, 77:92-98.

Relative Articles

[1]	Lulu ZHOU, Bing DONG, Jiejing XIN, Guanghua XU, Na LIU. Liver histopathological features of HBeAg-negative patients in the indeterminate phase of low-viral-load chronic hepatitis B virus infection[J]. Journal of Clinical Hepatology, 2025, 41(1): 52-56. doi: 10.12449/JCH250108
[2]	Manlei JIANG, Fei XU, Lunli ZHANG. Liver inflammation and fibrosis in HBV-infected patients with a low viral load[J]. Journal of Clinical Hepatology, 2023, 39(6): 1304-1307. doi: 10.3969/j.issn.1001-5256.2023.06.008
[3]	Yang ZHOU, Chaoxu FU, Min ZHOU, Lei XU, Mingyang LI, Yingsheng SHEN, Hongxin PIAO, Enyue YANG. Analysis of the results of hepatitis C antibody screening in 2020 in Yanbian area of China[J]. Journal of Clinical Hepatology, 2022, 38(7): 1509-1512. doi: 10.3969/j.issn.1001-5256.2022.07.011
[4]	Huikun ZHOU, Jianning JIANG, Minghua SU, Rongming WANG, Bobin HU, Deli DENG, Huilan WEI, Xianshuai LIANG, Wenming HE, Rongsheng GUO. Efficacy of entecavir versus tenofovir disoproxil fumarate in treatment of chronic hepatitis B patients with high viral load[J]. Journal of Clinical Hepatology, 2022, 38(3): 532-536. doi: 10.3969/j.issn.1001-5256.2022.03.008
[5]	Ran RuoXi, Xiao MengYao, Li AnLing, Liu SongMei. Clinical significance of the measurement of peripheral blood Epstein-Barr virus load in patients with HBV infection[J]. Journal of Clinical Hepatology, 2019, 35(4): 769-773. doi: 10.3969/j.issn.1001-5256.2019.04.013
[6]	Gu JiuLian, Liu ShouSheng, Li ChangFei, Xiao JianHan, Xin YongNing, Xuan ShiYing. Value of highly sensitive serum virological markers in hepatitis B patients with a low viral load[J]. Journal of Clinical Hepatology, 2018, 34(6): 1302-1307. doi: 10.3969/j.issn.1001-5256.2018.06.037
[7]	Zhang HuiFang, Li YongGuo. Influence of maintained hemodialysis on viral load in patients with end-stage renal disease with HBV infection[J]. Journal of Clinical Hepatology, 2017, 33(7): 1354-1357. doi: 10.3969/j.issn.1001-5256.2017.07.033
[8]	Li Qiang, Huang YuXian, Chen Liang. Independent predictive factors for significant liver histological changes in patients with HBe Ag-positive high-viral-load chronic HBV infection and a normal alanine aminotransferase level[J]. Journal of Clinical Hepatology, 2016, 32(7): 1310-1314. doi: 10.3969/j.issn.1001-5256.2016.07.019
[9]	Sun JianMin. Efficacy of thymosin α1 in chronic HBV infection patients with low viral load in immune-clearance or low-replication phase[J]. Journal of Clinical Hepatology, 2015, 31(2): 202-204. doi: 10.3969/j.issn.1001-5256.2015.02.014
[10]	Ding Chen, Pan Fan, Hu HaiZhang, Xiong RiHui, Li Song, Jiang Yi, Pan Chen. Efficacy of antiviral therapy in hepatocellular carcinoma patients with high HBV DNA levels after radical resection[J]. Journal of Clinical Hepatology, 2014, 30(7): 656-659. doi: 10.3969/j.issn.1001-5256.2014.07.021
[11]	Gu Bin, Huang HuiQin, Hou XiaoLan, Ning Feng, Zhang Yan, Li Lu. Relationship between hepatitis C virus genotypes and viral load in Chenzhou, China[J]. Journal of Clinical Hepatology, 2013, 29(11): 832-834. doi: 10.3969/j.issn.1001-5256.2013.11.008
[12]	Zhang HengBing. Effects of marine in the treatment of chronic hepatitis B patients with low viral load[J]. Journal of Clinical Hepatology, 2012, 28(3): 176-178.
[13]	Yang RuiFeng, Wei Lai. Detection of hepatitis C virus infection[J]. Journal of Clinical Hepatology, 2011, 27(1): 1-7.
[14]	Yan Yan, Xiu BingShui, Yin JiMing, Zhang HeQiu, Li Zhuo. Evaluation of cross-reactive antibody response to hypervariable region 1 of hepatitis C virus[J]. Journal of Clinical Hepatology, 2011, 27(8): 818-820.
[15]	Qu SiMai, Zhang Lin. Research advancement of antiviral treatment for chronic hepatitis C[J]. Journal of Clinical Hepatology, 2011, 27(12): 1331-1335.
[16]	Niu ChunYan, Gao BaoHua, Zheng JianYun, Wu FangXiong, Wang Wen, Luo JianMei, Zheng NaiQing. The correlations between HBV quantity in the liver tissue and the severity of liver tissue injury in chronic hepatitis B and hepatic cirrhosis[J]. Journal of Clinical Hepatology, 2011, 27(3): 277-279.
[17]	Yin ChiBiao, Zhang FuChun, Xian JianZhong, Cao Yang, Tang XiaoPing. Study of relationship between the serum viral load and ALT level and response to interferon therapy.[J]. Journal of Clinical Hepatology, 2004, 20(2): 97-98.

Supplements(0)

Cited By

Cited by

Periodical cited type(2)

1.	刘婷，武建明，姚亮，佟艳会，戚应杰. 国产高敏HCV-RNA定量试剂与国产普敏及进口高敏试剂一致性分析. 大医生. 2023(04): 1-6 .
2.	桂嵘，王勇军，周细国. 医疗机构中乙型肝炎病毒、丙型肝炎病毒、人类免疫缺陷病毒(1+2型)核酸检测策略专家共识. 临床输血与检验. 2020(06): 561-564 .

Other cited types(0)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (1358) PDF downloads(274)

Screening for hepatitis C virus infection in Peking University People's Hospital in 2015-2018

DOI: 10.3969/j.issn.1001-5256.2019.08.012